2-bromo-5-methyltriphenylphosphonium pyridine bromide

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-bromo-5-methyltriphenylphosphonium pyridine bromide
• 英文别名: ((6-bromopyridin-3-yl)methyl)triphenylphosphonium bromide；(6-Bromopyridin-3-yl)methyl-triphenylphosphanium;bromide；(6-bromopyridin-3-yl)methyl-triphenylphosphanium;bromide
• 化学式: Br*C₂₄H₂₀BrNP
• 分子量: 513.211
• InChiKey: DASIQCJAVXMCKA-UHFFFAOYSA-M

计算性质

• 辛醇/水分配系数(LogP)：
  2.34
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-Boc-3-氮杂环丁酮 、 2-bromo-5-methyltriphenylphosphonium pyridine bromide 在 sodium hydride 作用下， 以 N,N-二甲基甲酰胺 、 paraffin oil 为溶剂， 反应 2.0h， 以41.5%的产率得到tert-butyl 3-((6-bromopyridin-3-yl)methylene)azetidine-1-carboxylate
  参考文献：
  名称：

  [EN] FUMAGILLOL HETEROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING SAME
  [FR] COMPOSÉS HÉTÉROCYCLIQUES FUMAGILLOL, ET PROCÉDÉS CORRESPONDANTS DE FABRICATION ET D'UTILISATION

  摘要：

  本文披露了富马吉醇化合物及其在治疗医学疾病（如肥胖症）中的用途方法。提供了富马吉醇化合物的药物组合物和制备方法。这些化合物被认为具有对蛋氨酸氨肽酶2的活性。

  公开号：

  WO2017027684A1
• 作为产物：
  描述：

  2-溴-5-甲基吡啶 在 N-溴代丁二酰亚胺(NBS) 作用下， 以 四氯化碳 为溶剂， 反应 3.5h， 生成 2-bromo-5-methyltriphenylphosphonium pyridine bromide
  参考文献：
  名称：

  Substituted Dipyridylethenes and -ethynes and Key Pyridine Building Blocks

  摘要：

  合成了多种新的2,5-二取代吡啶。通过还原烟酸3、氨基二甲基吡啶6的水解或5-溴吡啶12和14与丁基锂在DMF中的反应，得到了2-取代的5-醛基吡啶8、15a-b。双吡啶乙烯16a-b,e通过Wadsworth-Emmons反应与吡啶基膦酸酯7合成，或者通过McMurry反应将醛偶联形成烯烃16c-d。在双吡啶乙烯16a-d的C=C双键溴化后，经过1,2-双吡啶-1,2-二溴乙烷17a-d的消除，得到了双吡啶乙炔18a-d。

  DOI：

  10.1055/s-1994-25411

文献信息

• [EN] COMPOUNDS AND THEIR USE TO TREAT HISTAMINE H3 RELATED DISORDERS<br/>[FR] COMPOSÉS ET LEUR UTILISATION POUR LE TRAITEMENT DE TROUBLES ASSOCIÉS AU RÉCEPTEUR H3 DE L'HISTAMINE
  申请人：TAKEDA PHARMACEUTICAL

  公开号：WO2013027001A1

  公开（公告）日：2013-02-28

  The present invention provides compounds of formula (1) and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, m, n, p, q, Q1, Q2, Q3, Q4, Q5, Q6, X1, X2, X3, X4, A1 and L1, are as defined in the specification, processes for their preparation, pharmaceutical compositions containing them and their use in therapy.

  本发明提供了式（1）的化合物及其药学上可接受的盐，其中R1、R2、R3、R4、R5、R6、R7、R8、R9、R10、R11、R12、R13、R14、R15、R16、R17、R18、R19、R20、m、n、p、q、Q1、Q2、Q3、Q4、Q5、Q6、X1、X2、X3、X4、A1和L1如规范中所定义，其制备方法，含有它们的药物组合物以及它们在治疗中的用途。
• Triple Helical Ir(ppy) ₃ Phenylene Cage Prepared by Diol‐Mediated Benzannulation: Synthesis, Resolution, Absolute Stereochemistry and Photophysical Properties
  作者：Hiroki Sato、Michelle A. Blemker、Garrett Hellinghausen、Daniel W. Armstrong、Jordan W. Nafie、Sean T. Roberts、Michael J. Krische

  DOI：10.1002/chem.201902122

  日期：2019.7.2

  Cyclometalation of a triple helical N‐doped phenylene cage prepared by ruthenium(0)‐catalyzed diol–diene benzannulation delivers a chiral, conformationally constrained Ir(ppy)3 analogue. Like the parent complex, fac‐Ir(ppy)3, the iridium‐containing PAH‐cage is phosphorescent, but displays enhanced resistance to oxygen quenching.

  通过钌（0）催化的二醇-二烯苯环合制备的三螺旋N掺杂亚苯基笼型的环金属化可提供手性，构象受限的Ir（ppy）3类似物。像母体复合物fac- Ir（ppy）3一样，含铱的PAH笼是磷光的，但对氧猝灭的抵抗力增强。
• MATRIX METALLOPROTEINASE INHIBITORS
  申请人：Sattigeri Viswajanani J.

  公开号：US20100081610A1

  公开（公告）日：2010-04-01

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及β-羟基和氨基取代的羧酸，其作为基质金属蛋白酶抑制剂，尤其是对映异构体纯的β-羟基羧酸，以及合成该类化合物和含有本发明化合物的制药组合物的相关过程。本发明化合物在治疗各种炎症、自身免疫和过敏性疾病方面有用，例如治疗哮喘、类风湿性关节炎、慢性阻塞性肺疾病、鼻炎、骨关节炎、银屑病性关节炎、牛皮癣、肺纤维化、创伤愈合障碍、肺炎炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、新内膜增生导致再狭窄和缺血性心力衰竭、中风、肾脏疾病、肿瘤转移以及其他以基质金属蛋白酶过度表达和过度活化为特征的炎症性疾病的方法中使用该化合物。
• Matrix metalloproteinase inhibitors
  申请人：Ranbaxy Laboratories Limited

  公开号：EP2322507A1

  公开（公告）日：2011-05-18

  The present invention relates to β-hydroxy and amino substituted carboxylic acids, which act as matrix metalloprotease inhibitors, particularly diastereomerically pure β-hydroxy carboxylic acids, corresponding processes for the synthesis of and pharmaceutical compositions containing the compounds of the present invention. Compounds of the present invention are useful in the treatment of various inflammatory, autoimmune and allergic diseases, such as methods of treating asthma, rheumatoid arthritis, COPD, rhinitis, osteoarthritis, psoriatic arthritis, psoriasis, pulmonary fibrosis, wound healing disorders, pulmonary inflammation, acute respiratory distress syndrome, perodontitis, multiple sclerosis, gingivitis, atherosclerosis, neointimal proliferation, which leads to restenosis and ischemic heart failure, stroke, renal diseases, tumor metastasis, and other inflammatory disorders characterized by the over-expression and over-activation of a matrix metalloproteinase using the compounds.

  本发明涉及作为基质金属蛋白酶抑制剂的β-羟基和氨基取代的羧酸，特别是非对映异构纯的β-羟基羧酸，以及合成本发明化合物的相应工艺和含有本发明化合物的药物组合物。本发明的化合物可用于治疗各种炎症、自身免疫性和过敏性疾病，如治疗哮喘、类风湿性关节炎、慢性阻塞性肺病、鼻炎、骨关节炎、银屑病关节炎、牛皮癣、肺纤维化、伤口愈合障碍、肺部炎症、急性呼吸窘迫综合征、牙周炎、多发性硬化症、多发性骨髓瘤、多发性硬化症、多发性硬化症的方法、牙周炎、多发性硬化症、牙龈炎、动脉粥样硬化、导致再狭窄和缺血性心力衰竭的新内膜增生、中风、肾脏疾病、肿瘤转移，以及其他以基质金属蛋白酶过度表达和过度激活为特征的炎症性疾病。
• Fumagillol heterocyclic compounds and methods of making and using same
  申请人：Zafgen, Inc.

  公开号：US10023561B2

  公开（公告）日：2018-07-17

  Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

  本文部分公开了烟曲霉素化合物和用于治疗肥胖等疾病的方法。提供了药物组合物和制造烟嘧酚化合物的方法。这些化合物对蛋氨酰氨基肽酶 2 具有活性。